This major expansion project will provide a four-fold increase in gene therapy process development and analytical capacity accommodating viral vector, DNA ...
With many of the largest CDMOs now running at capacity, drug sponsors will need to focus on mitigating risk and building resiliency when using smaller or m...
© 2026 Biopharma Boardroom. All Rights Reserved.
